Navigation Links
TYRX AIGISRx antibacterial envelope shows low infection rate, high CIED procedure success
Date:10/19/2010

Monmouth Junction, NJ (October 19, 2010) Patients undergoing CIED (Cardiac Implantable Electronic Device) implantation with TYRX, Inc.'s FDA-cleared AIGISRx Antibacterial Envelope enjoyed a 99.5% rate of successful implantation with an overall infection rate of 0.48% in the first 1.9 months following the procedure, as reported in newly published results of TYRX's COMMAND Clinical Study. There were no infections in patients receiving initial implantations of pacemakers, implantable cardioverter-defibrillators, or cardiac resynchronization therapy devices. The infection rate within the highest risk cohort, ICD/CRT-D replacements/revisions, demonstrated 70% fewer infections than some previous studies.

Results of the COMMAND Study included data from 642 consecutive CIED implantation or revision/replacement procedures utilizing the AIGISRx Antibacterial Envelope at 10 U.S. medical centers. The results were published in the October on-line issue of Pacing and Clinical Electrophysiology, the official journal of the International Cardiac Pacing and Electrophysiology Society.

"The COMMAND Study provides additional evidence that the AIGISRx Antibacterial Envelope offers physicians an effective means for addressing the significant unmet clinical need for additional CIED infection prophylaxis as described in the American Heart Association and Heart Rhythm Society CRM Infection Guidelines published earlier this year," stated Heather Bloom, MD, Director of Electrophysiology at the Atlanta VA Medical Center, Assistant Professor of Medicine, Emory University, and lead author on the COMMAND Study report.

The COMMAND Study, the first clinical study of patients undergoing CIED implantation with the AIGISRx Antibacterial Envelope, was a retrospective cohort study in patients receiving implantation of a pacemaker, implanted cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device. The primary endpoints of the study were successful CIED implantation and CIED infection. The study enrolled a high proportion of patients with established risk factors for CIED infection: 67.5% underwent revision or replacement procedures, and 36.5% had procedures with a CRT- defibrillator (CRT-D).

Currently, more than 500,000 CIEDs are implanted in the United States each year. CIED infections occur in association with 1-7% of these devices and are associated with significant morbidity, mortality, and expense. The AIGISRx Antibacterial Envelope is designed to reduce infection risk by eluting the antibiotics minocycline and rifampin for 7-10 days after implantation with the CIED. This antibiotic combination has been shown to reduce infections associated with medical devices in multiple randomized controlled trials.

TYRX Chief Medical Officer, Daniel Lerner, M.D. commented, "Previous studies have demonstrated that coating or impregnating medical devices with the antibiotics minocycline and rifampin significantly reduces device-related infections. The COMMAND Study is important because it generated data on the clinical performance of an FDA-cleared device that provides sustained local delivery of these antibiotics in the generator pocket after CIED implantation, in a population at high risk for CIED infection."


'/>"/>

Contact: Joan Kureczka
Joan@kureczka-martin.com
Kureczka/Martin Associates
Source:Eurekalert

Related biology news :

1. Antibacterial peptide could aid in treating soldiers burn wound infections
2. Antibacterial silver nanoparticles are a blast
3. Mineral studies advance antibacterial alternatives
4. RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors
5. Shifting forms: Penn study shows how variations of same protein affect immune response
6. Faster CARS, less damage: NIST chemical microscopy shows potential for cell diagnostics
7. Meta-analysis shows no heart benefits for folic acid supplements
8. Investigational ovarian cancer drug shows promise against platinum resistant disease
9. New study shows benefits of Bt corn to farmers
10. T cell discovery shows promise for Type 1 diabetes treatment: UBC-CFRI study
11. 1st census shows life in planet ocean is richer, more connected, more altered than expected
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, ... on their recent FDA Class II 510(k) clearance for their flagship medical device, ... commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies ...
(Date:12/2/2016)... leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI HIV ... http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton Health ... Self Test to 350 pharmacy representatives in Nairobi and Mombasa, ...
(Date:11/30/2016)... , Nov. 30, 2016 Biotest Pharmaceuticals ... is pleased to announce the addition of its newest ... Kearney, Nebraska . The 15,200 square foot ... November 29th, 2016 and brings the total number of ... Ileana Carlisle , BPC,s Chief Executive Officer said ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
Breaking Biology Technology: